IBDEI0VN ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14089,1,3,0)
 ;;=3^Myopathy,Alcoholic
 ;;^UTILITY(U,$J,358.3,14089,1,4,0)
 ;;=4^G72.1
 ;;^UTILITY(U,$J,358.3,14089,2)
 ;;=^5004096
 ;;^UTILITY(U,$J,358.3,14090,0)
 ;;=G72.81^^83^821^95
 ;;^UTILITY(U,$J,358.3,14090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14090,1,3,0)
 ;;=3^Myopathy,Critical Illness
 ;;^UTILITY(U,$J,358.3,14090,1,4,0)
 ;;=4^G72.81
 ;;^UTILITY(U,$J,358.3,14090,2)
 ;;=^328484
 ;;^UTILITY(U,$J,358.3,14091,0)
 ;;=G72.0^^83^821^96
 ;;^UTILITY(U,$J,358.3,14091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14091,1,3,0)
 ;;=3^Myopathy,Drug-Induced
 ;;^UTILITY(U,$J,358.3,14091,1,4,0)
 ;;=4^G72.0
 ;;^UTILITY(U,$J,358.3,14091,2)
 ;;=^5004095
 ;;^UTILITY(U,$J,358.3,14092,0)
 ;;=G72.41^^83^821^97
 ;;^UTILITY(U,$J,358.3,14092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14092,1,3,0)
 ;;=3^Myopathy,Inclusion Body Myositis
 ;;^UTILITY(U,$J,358.3,14092,1,4,0)
 ;;=4^G72.41
 ;;^UTILITY(U,$J,358.3,14092,2)
 ;;=^5004098
 ;;^UTILITY(U,$J,358.3,14093,0)
 ;;=G72.49^^83^821^98
 ;;^UTILITY(U,$J,358.3,14093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14093,1,3,0)
 ;;=3^Myopathy,Inflammatory/Immune NEC
 ;;^UTILITY(U,$J,358.3,14093,1,4,0)
 ;;=4^G72.49
 ;;^UTILITY(U,$J,358.3,14093,2)
 ;;=^5004099
 ;;^UTILITY(U,$J,358.3,14094,0)
 ;;=G72.2^^83^821^99
 ;;^UTILITY(U,$J,358.3,14094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14094,1,3,0)
 ;;=3^Myopathy,Other Toxic Agents
 ;;^UTILITY(U,$J,358.3,14094,1,4,0)
 ;;=4^G72.2
 ;;^UTILITY(U,$J,358.3,14094,2)
 ;;=^5004097
 ;;^UTILITY(U,$J,358.3,14095,0)
 ;;=G72.3^^83^821^100
 ;;^UTILITY(U,$J,358.3,14095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14095,1,3,0)
 ;;=3^Myopathy,Periodic Paralysis
 ;;^UTILITY(U,$J,358.3,14095,1,4,0)
 ;;=4^G72.3
 ;;^UTILITY(U,$J,358.3,14095,2)
 ;;=^335326
 ;;^UTILITY(U,$J,358.3,14096,0)
 ;;=G72.9^^83^821^101
 ;;^UTILITY(U,$J,358.3,14096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14096,1,3,0)
 ;;=3^Myopathy,Unspec
 ;;^UTILITY(U,$J,358.3,14096,1,4,0)
 ;;=4^G72.9
 ;;^UTILITY(U,$J,358.3,14096,2)
 ;;=^5004101
 ;;^UTILITY(U,$J,358.3,14097,0)
 ;;=M60.9^^83^821^102
 ;;^UTILITY(U,$J,358.3,14097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14097,1,3,0)
 ;;=3^Myositis,Unspec
 ;;^UTILITY(U,$J,358.3,14097,1,4,0)
 ;;=4^M60.9
 ;;^UTILITY(U,$J,358.3,14097,2)
 ;;=^5012409
 ;;^UTILITY(U,$J,358.3,14098,0)
 ;;=M79.2^^83^821^103
 ;;^UTILITY(U,$J,358.3,14098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14098,1,3,0)
 ;;=3^Neuralgia & Neuritis,Unspec
 ;;^UTILITY(U,$J,358.3,14098,1,4,0)
 ;;=4^M79.2
 ;;^UTILITY(U,$J,358.3,14098,2)
 ;;=^5013322
 ;;^UTILITY(U,$J,358.3,14099,0)
 ;;=M54.81^^83^821^104
 ;;^UTILITY(U,$J,358.3,14099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14099,1,3,0)
 ;;=3^Neuralgia,Occipital
 ;;^UTILITY(U,$J,358.3,14099,1,4,0)
 ;;=4^M54.81
 ;;^UTILITY(U,$J,358.3,14099,2)
 ;;=^5012312
 ;;^UTILITY(U,$J,358.3,14100,0)
 ;;=M89.70^^83^821^106
 ;;^UTILITY(U,$J,358.3,14100,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14100,1,3,0)
 ;;=3^Osseous Defect,Major,Unspec Site
 ;;^UTILITY(U,$J,358.3,14100,1,4,0)
 ;;=4^M89.70
 ;;^UTILITY(U,$J,358.3,14100,2)
 ;;=^5015085
 ;;^UTILITY(U,$J,358.3,14101,0)
 ;;=M79.81^^83^821^105
 ;;^UTILITY(U,$J,358.3,14101,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14101,1,3,0)
 ;;=3^Nontraumatic Hematoma,Soft Tissue
 ;;^UTILITY(U,$J,358.3,14101,1,4,0)
 ;;=4^M79.81
 ;;^UTILITY(U,$J,358.3,14101,2)
 ;;=^5013356
